<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4710">
  <stage>Registered</stage>
  <submitdate>11/11/2014</submitdate>
  <approvaldate>11/11/2014</approvaldate>
  <nctid>NCT02297594</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability and PK Study of AK0529 in Healthy Human</studytitle>
    <scientifictitle>A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of AK0529 When Administered Orally in Healthy Male and Female Adult Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AK0529-1001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Respiratory Syncytial Virus Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AK0529
Treatment: drugs - Placebo

Experimental: AK0529 - Generic name: AK0529 Dosage Form: capsule

Placebo Comparator: Placebo - Sugar placebo


Treatment: drugs: AK0529
AK0529 capsule for oral administration

Treatment: drugs: Placebo
Sugar placebo capsule for oral administration

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with adverse events, serious adverse events</outcome>
      <timepoint>Screening to Day 14 - 21</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of single dose study: Area Under Curve (AUC)</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of single dose study: Observed Maximum plasma concentration (Cmax)</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of single dose study: half-life (t1/2)</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of single dose study: time to maximum plasma concentration (tmax)</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of single dose study: Volume of distribution</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of single dose study: Clearance</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of multiple dose study:Area Under Curve (AUC)</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of multiple dose study: Observed Maximum plasma concentration (Cmax)</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of multiple dose study: half-life (t1/2)</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of multiple dose study: time to maximum plasma concentration (tmax)</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of multiple dose study:Volume of distribution</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of multiple dose study: clearance</outcome>
      <timepoint>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day1 and pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 hours post-dose on Day 7 and at 24 hours (Day 8) and at 48 hours (Day 9)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Must be healthy males, or healthy females of non-childbearing potential or surgically
             sterilized or post-menopausal (amenorrhea for at least 1 year and confirmed by a
             follicle stimulating hormone [FSH] result of &gt; 20 IU/mL).

          2. Must be aged 18 to 55 years of age inclusive.

          3. Must have body mass index (BMI) of 18.0 to 31.0 kg/m2 inclusive.

          4. Must have total body weight =50 kg at screening but =100 Kg.

          5. Must be willing and able to communicate and participate in the whole study.

          6. Must provide written informed consent.

          7. Must agree to use an adequate method of contraception (as defined in Section 4.2.1).

          8. Must have AST, ALT, total bilirubin, urea, creatinine and hemoglobin within the
             laboratory reference range at screening and Day -1.

          9. Must have QTcF &lt;450 ms, QTcB &lt;450 ms and PR interval &lt;210 ms for screening, Day -1 and
             pre-dose ECG measurements, and not have any degree of heart block or conduction
             abnormality.

         10. Must have serology demonstrating they are free from infection with hepatitis B,
             hepatitis C, and human immunodeficiency virus (HIV-1 and HIV-2)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Male subjects who have currently pregnant partners or who have partners planning to
             become pregnant during the duration of the study.

          2. Evidence or history of clinical significant oncological, pulmonary, chronic
             respiratory, hepatic, cardiovascular, hematological, metabolic, neurological,
             immunological, nephrological, endocrine or psychiatric disease, or current infection.

          3. Clinically relevant (as decided by the investigator and the medical monitor)
             abnormalities in the ECG (12 standard leads) including any degree of heart block,
             including asymptomatic bundle branch block.

          4. Family history of sudden death or of congenital prolongation of the QTc interval or
             known congenital prolongation of the QTc interval or any clinical condition known to
             prolong the QTc interval.

          5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.

          6. Electrolyte disturbances, particularly hypokalemia hypocalcemia or hypomagnesemia.

          7. Any condition that could possibly affect drug absorption, e.g. gastrectomy or
             diarrhea.

          8. History of post-antibiotic colitis.

          9. History of any drug or alcohol abuse in the past 2 years prior to screening.

         10. Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week
             (1 unit = 400 mL beer, 25 mL of 40% spirit or a 75 mL glass of wine).

         11. Subjects who have a urine cotinine greater than 500 ng/mL at screening will be
             excluded. Subjects who are tobacco users (including smokers and users of snuff,
             chewing tobacco and other nicotine or nicotine-containing products) must have stopped
             use at least 90 days before screening.

         12. Receipt of an investigational drug or participation in another clinical research study
             within 90 days prior to drug administration.

         13. Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee.

         14. Subjects who have previously been enrolled and dosed in this study, except subjects
             undergoing repeat dosing in Cohort 4F (the fed PK cohort of the SAD part of the
             study).

        Other protocol defined inclusion/exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>74</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Q-Pharm Pty Ltd QIMR Berghofer &amp; Royal Brisbane and Women's Hospital Campus - Brisbane</hospital>
    <postcode>4006 - Brisbane</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ark Biosciences Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the safety, tolerability and PK of single and multiple
      ascending dose of AK0529 when administered orally in healthy subjects</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02297594</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Griffin, MD</name>
      <address>Q-Pharm Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>